Abstracts tagged "SLE"

Abstract Number: 2662 • 2014 ACR/ARHP Annual Meeting
Attribution Protocol and Clinical Significance of Neuropsychiatric Manifestations in Childhood-Onset Systemic Lupus Erythematosus
Renata Barbosa¹, Karina Oliveira Peliçari², Aline T. Lapa³, Nailu A. Sinicato³, Mariana Postal³, Roberto Marini⁴, Marcelo Govoni Sr.⁵ and Simone Appenzeller⁶, ¹Medicine, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, ²State University of Campinas, Campinas, Brazil, ³Medicine, State University of Campinas, Campinas, Brazil, ⁴Departament of Pediatrics, State University of Campinas, Campinas, Brazil, ⁵Department of Clinical medicine and Experimental, University of Ferrara, Ferrara, Italy, ⁶Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is caused by an imbalance of the immune system and may lead to injury and dysfunction of various systems and…
Abstract Number: 1954 • 2014 ACR/ARHP Annual Meeting
Successfull Long-Term Depletion of Memory Plasma Cells Requires a Combined Depletion of Plasma Cells and Their Precurors in NZB/W Mice
Adriano Taddeo¹, Laleh Khodadadi¹, Qingyu Cheng², Andreas H. Radbruch¹, Falk Hiepe³ and Bimba F. Hoyer², ¹Deutsches Rheumaforschungszentrum, Berlin, Germany, ²Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Germany, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany
Background/Purpose: Autoantibodies contribute significantly to the pathogenesis of systemic lupus erythematosus (SLE). The long-lived plasma cells (LLPC) secreting such autoantibodies are unfortunately refractory to conventional…
Abstract Number: 1607 • 2014 ACR/ARHP Annual Meeting
B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare
Mikhail Olferiev¹, Kyriakos A. Kirou² and Mary K. Crow³, ¹Research, HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose Lupus flare reflects an increase of disease activity that is associated with significant morbidity and accumulation of tissue damage. Prediction and prevention of lupus…
Abstract Number: 699 • 2014 ACR/ARHP Annual Meeting
Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes
Nimrit Dhillon¹, Dominique Ibanez¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Osteonecrosis is a serious comorbidity of systemic lupus erythematosus (SLE). The reported frequency of symptomatic osteonecrosis in SLE is variable, ranging from 4% to…
Abstract Number: 2636 • 2014 ACR/ARHP Annual Meeting
Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE)
John A. Reynolds¹, David W. Ray², Terence O'Neill³, Yvonne Alexander⁴ and Ian N. Bruce^5,6, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁴Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose SLE patients have an increased risk of cardiovascular disease (CVD). Vitamin D deficiency has been associated with both CVD risk factors and subclinical CVD…
Abstract Number: 1923 • 2014 ACR/ARHP Annual Meeting
Vitamin D Restores Lupus Myeloid Angiogenic Cell Function Via Down-Regulation of IP-10/CXCL-10
John A. Reynolds¹, David W. Ray², Yvonne Alexander³ and Ian N. Bruce⁴, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose Endothelial repair is important for the maintenance of vascular integrity and is impaired in patients with SLE. Myeloid angiogenic cells (MACs) contribute to endothelial…
Abstract Number: 1604 • 2014 ACR/ARHP Annual Meeting
IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria
Rufei Lu^1,2, Melissa E. Munroe³, Joel M. Guthridge², Krista M. Bean², Dustin Fife², John B. Harley⁴, Judith A. James⁵ and Michael P. Keith⁶, ¹Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose Systemic Lupus Erythematosus (SLE) is a clinically diverse autoimmune disease that often begins with a pre-disease period of autoantibody production and symptom accrual.…
Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
John G. Hanly¹, Amyn Sayani², Steve Doucette³, Sandra Iczkovitz² and Jorge Alfonso Ross², ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ³Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…
Abstract Number: 2955 • 2014 ACR/ARHP Annual Meeting
The Impact of Northern European Ancestry and Susceptibility Loci on the Risk of Lupus Nephritis
Sarah French¹, Kimberly E. Taylor², Sharon A. Chung¹, Joanne Nitiham³, Michelle Petri⁴, Peter K. Gregersen⁵, Ward Ortmann⁶, Annette T. Lee⁷, Timothy W. Behrens⁶, Susan Manzi⁸, F. Yesim Demirci⁹, M. Ilyas Kamboh¹⁰, Robert R. Graham⁶, Michael F. Seldin¹¹ and Lindsey A. Criswell³, ¹School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁶ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Human Genetics, University of Pittsburgh, Pittsburgh, PA, ¹¹Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA
Background/Purpose Lupus nephritis (LN) has a higher prevalence among African Americans, Hispanics, and Asians compared to Caucasians. Significant differences in SLE severity also exist within…
Abstract Number: 2652 • 2014 ACR/ARHP Annual Meeting
Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies
Anne B Tjensvoll¹, Maria B Lauvsnes², Shunsei Hirohata³, Jan T Kvaløy⁴, Mona K Beyer⁵, Erna Harboe⁶, Lasse G Gøransson⁶, Ole J Greve⁷ and Roald Omdal⁸, ¹Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ²Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁴Research Department, Stavanger University Hospital, Stavanger, Norway, ⁵Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ⁶Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁷Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Headache, especially migraine, is frequent and one of the most common neuropsychiatric manifestations in systemic lupus erythematosus (SLE). A possible mechanism for this is…
Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting
Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Laurence S Magder¹, Eric Zollars², Jadwiga Bienkowska³, Chris Stebbins⁴, Carrie Wager⁵, Linda Burkly⁶, Nicolas Wisniacki⁷, Ann Ranger⁸ and Michelle Petri⁹, ¹Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Translational Medicine, Biogen Idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec, Cambridge, MA, ⁷Formerly with Biogen Idec, Cambridge, MA, ⁸14 Cambridge Center, Biogen Idec, Cambridge, MA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…
Abstract Number: 1620 • 2014 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)
Andy Hollins¹, Michael Duryee², Michelene Hearth-Holmes³, Ted R. Mikuls¹, Zhixin Zhang⁴, Kaihong Su⁵ and Geoffrey M. Thiele⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose Studies have shown that malondialdehyde-acetaldehyde (MAA) is formed as a result of lipid peroxidation of cellular membranes and is capable of binding or adducting…
Abstract Number: 686 • 2014 ACR/ARHP Annual Meeting
Clinicians Approaches to the Management of Background Therapy in SLE Patients in Clinical Remission: Results of an International Survey
Pintip Ngamjanyaporn^1,2, Ian Bruce³, Ben Parker⁴ and Jamie Sergeant¹, ¹Institute of Inflammation and Repair School of translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ²Internal Medicine, Mahidol University, Bangkok, Thailand, ³Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: At present there is no consensus on what constitutes a remission in SLE. In particular it is not clear how background therapy should be…
Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting
Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE
Jens Y. Humrich¹, Caroline von Spee-Mayer¹, Elise Siegert¹, Angelika Rose¹, Tobias Alexander², Falk Hiepe¹, Andreas Radbruch³, Gerd Burmester⁴ and Gabriela Riemekasten¹, ¹Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 2619 • 2014 ACR/ARHP Annual Meeting
Low Socioeconomic Status (SES) As Measured By Education Is (not) Associated with Worse Outcome in SLE: Data from the 1000 Canadian Faces of Lupus
Angela George¹, Christine Peschken², Earl Silverman³, Christian A. Pineau⁴, C Douglas Smith⁵, Hector Arbillaga⁶, Michel Zummer⁷, Ann Clarke⁸, Sasha Bernatsky⁹, Marie Hudson¹⁰, Carol A. Hitchon¹¹, Paul R. Fortin¹² and Janet E. Pope¹³, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³Pediatrics/Rheumatology, Toronto Hospital for Sick Children, U of Toronto, Toronto, ON, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵The Arthritis Centre, TOH Riverside Campus, Ottawa, ON, Canada, ⁶Medicine/Rheumatology, Lethbridge Rheumatology practice, Lethbridge, AB, Canada, ⁷Medicine/Rheumatology, U of Montreal, Montreal, QC, Canada, ⁸Medicine/Allergy, U of Calgary, Calgary, AB, Canada, ⁹Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ¹⁰Medicine/Rheumatology, McGill University, Montreal, QC, Canada, ¹¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹²Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ¹³St Joseph Health Care, London, ON, Canada
Background/Purpose: To determine whether socioeconomic status, as measured by education, impacts disease activity (measured by SLAM-2, SLEDAI-2K) or disease damage (measured by SLICC SDI) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].